- Home
- ATNF vs GRI Comparison
ATNF vs GRI Comparison
Compare ATNF & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNF
- GRI
- Stock Information
- Founded
- ATNF 2016
- GRI 2018
- Country
- ATNF United States
- GRI United States
- Employees
- ATNF N/A
- GRI N/A
- Industry
- ATNF Biotechnology: Pharmaceutical Preparations
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- ATNF Health Care
- GRI Health Care
- Exchange
- ATNF Nasdaq
- GRI Nasdaq
- Market Cap
- ATNF 1.8M
- GRI 1.5M
- IPO Year
- ATNF N/A
- GRI N/A
- Fundamental
- Price
- ATNF $1.42
- GRI $0.36
- Analyst Decision
- ATNF
- GRI
- Analyst Count
- ATNF 0
- GRI 0
- Target Price
- ATNF N/A
- GRI N/A
- AVG Volume (30 Days)
- ATNF 46.0K
- GRI 801.1K
- Earning Date
- ATNF 11-07-2024
- GRI 11-13-2024
- Dividend Yield
- ATNF N/A
- GRI N/A
- EPS Growth
- ATNF N/A
- GRI N/A
- EPS
- ATNF N/A
- GRI N/A
- Revenue
- ATNF N/A
- GRI N/A
- Revenue This Year
- ATNF N/A
- GRI N/A
- Revenue Next Year
- ATNF $54.15
- GRI N/A
- P/E Ratio
- ATNF N/A
- GRI N/A
- Revenue Growth
- ATNF N/A
- GRI N/A
- 52 Week Low
- ATNF $1.31
- GRI $0.30
- 52 Week High
- ATNF $12.03
- GRI $154.70
- Technical
- Relative Strength Index (RSI)
- ATNF 35.64
- GRI 32.69
- Support Level
- ATNF $1.38
- GRI $0.30
- Resistance Level
- ATNF $1.58
- GRI $0.39
- Average True Range (ATR)
- ATNF 0.16
- GRI 0.06
- MACD
- ATNF -0.05
- GRI 0.00
- Stochastic Oscillator
- ATNF 4.60
- GRI 19.44
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.